Epilepsy & Seizures
News
Epilepsy in Patients With Alzheimer’s Disease
G. Peter Gliebus, MD; Ahmad Al-Sibai, MD; and Michelle L. Dougherty, MD
June 2018—Providers should have a high index of suspicion for seizure disorders in patients with Alzheimer’s disease.
BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th
Friday, June 01, 2018—Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regar…
New Type of Vertigo Defined That May Be Treatable
Wednesday, May 23, 2018—Neurologists have defined a new type of vertigo with no known cause (Neurology. 2018:published online May 23). The authors have differentiated this type of vertigo from seriou…
Growing Evidence for Cannabidiol to Treat Lennox Gastaut Syndrome and Dravet Syndrome
Thursday, May 17, 2018—Results of a phase 3 clinical trial comparing adjunctive treatment with cannabidiol (CBD) (Epidiolex; GW Pharmaceuticals/Greenwich Biosciences, Carlsbad, CA) to placebo showed…
Potential New Rescue Therapy for Cluster Seizures, Midazolam Nasal Spray, Acquired by UCB
Wednesday, May 16, 2018—UCB has announced an agreement to acquire the rights to midazolam nasal spray (USL261), intended as a rescue therapy for acute repetitive series (ARS), or cluster seizures. &n…
Premarket Approval for Deep Brain Stimulation for Treatment of Patients with Refractory Partial Onset Seizures
Tuesday, May 01, 2018—The Food and Drug Administration (FDA) has granted premarket approval of deep brain stimulation (DBS) therapy to Medtronic (Dublin, Ireland) for adjunctive treatment to reduce…
Obstructive Sleep Apnea and Epilepsy
Michelle L. Dougherty, MD; and Karin G. Johnson, MD
May 2018—It is important to consider comorbid sleep disorders for patients with epilepsy.
Perampanel Safety, Efficacy, and Predictors of Major Response
Friday, April 27, 2018—Perampanel (FYCOMPA; Eisai, Woodcliff Lake, NJ) is approved for use as monotherapy for treatment of partial-onset seizures (POS) with or without secondarily generalized seizur…
